Laboratory Corporation of America Holdings with ticker code (LH) now have 14 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $270.00 and $220.00 suggesting an average analyst share price target price of $245.71. (at the time of writing). Given that the stocks previous close was at $222.13 this would imply there is now a potential upside of 10.6%. The day 50 moving average is $223.57 while the 200 day moving average is $209.09. The company has a market capitalization of 18.18B. The stock price is currently at: $216.64 USD
The potential market cap would be $20,105,562,558 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 50.03, revenue per share of $139.63 and a 3.81% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
